Loading...

Louis VanderMolen, MD

Title(s)Professor of Clinical Medicine
Phone+1 323 226 7593
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    Phi Beta Kappa1977Elected Member
    Baylor College of Medicine1983  - 1984Chief Resident, Internal Medicine
    Orange County Medical Association2006  - 2013Physician of Excellence Award

    Collapse Overview 
    Collapse Overview
    Dr. VanderMolen earned his medical degree from Loyola University Stritch School of Medicine. He performed his Internal Medicine Internship and Residency from Baylor College of Medicine- Texas Medical Center. He then went on to complete two fellowships, the first in hematology at Baylor, and the second in oncology at National Cancer Institute- Clinical Oncology Program.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Dillman RO, Barth NM, VanderMolen LA, Mahdavi K, McClure SE. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm. 2012 Aug; 27(6):337-43. PMID: 22804456.
      View in: PubMed
    2. Dillman RO, Barth NM, VanderMolen LA, Fong WH, Mahdavi KK, McClure SE. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer? Cancer Biother Radiopharm. 2011 Jun; 26(3):273-7. PMID: 21711094.
      View in: PubMed
    3. Kim B, Dillman RO, Chen P, Hafer R, Cox C, Barth N, Carroll RM, VanderMolen L, Nguyen M, Huang J, Minion A, Plunkett M, Mackintosh R. A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced head and neck cancer. Am J Otolaryngol. 2012 Jan-Feb; 33(1):93-7. PMID: 21524816.
      View in: PubMed
    4. Dillman RO, Barth NM, VanderMolen LA, Allen K, Beutel LD, Chico S. High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants. Am J Clin Oncol. 2005 Jun; 28(3):281-8. PMID: 15923802.
      View in: PubMed
    5. Dillman R, Barth N, Vandermolen L, Mahdavi K, Beutel L, de Leon C, DePriest C, Nayak S. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother Radiopharm. 2004 Oct; 19(5):570-80. PMID: 15650449.
      View in: PubMed
    6. Dillman RO, O'Connor AA, Simpson L, Barth NM, VanderMolen LA, Vanderplas P. Does continuous-infusion interleukin-2 increase survival in metastatic melanoma? Am J Clin Oncol. 2003 Apr; 26(2):141-5. PMID: 12714884.
      View in: PubMed
    7. VanderMolen LA, Sheehy PF, Dillman RO. Successful treatment of transitional cell carcinoma of the urethra with chemotherapy. Cancer Invest. 2002; 20(2):206-7. PMID: 11901541.
      View in: PubMed
    8. Dillman RO, Barth NM, VanderMolen LA, Garfield DH, De Leon C, O'Connor AA, Mahdavi K, Nayak SK. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma. Cancer Biother Radiopharm. 2001 Feb; 16(1):47-54. PMID: 11279797.
      View in: PubMed
    9. New MI, Obeid J, Wilson RC, Cabrera MS, Goseco A, Macapagal MC, Marshall I, Nimkarn S, Quintos JB, Ten S, Ugrasbul F, Vandermolen L, Harbison MD. Profile of the pediatric endocrine clinic at New York-Presbyterian Hospital, New York Weill Cornell Center. J Clin Endocrinol Metab. 1999 Dec; 84(12):4444-9. PMID: 10599700.
      View in: PubMed
    10. Dillman RO, Wiemann MC, VanderMolen LA, Bury MJ, DePriest C, Church C. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: a phase II trial of the Cancer Biotherapy Research Group (formerly the National Biotherapy Study Group). Cancer Biother Radiopharm. 1997 Aug; 12(4):249-55. PMID: 10851472.
      View in: PubMed
    11. Gause BL, Sznol M, Kopp WC, Janik JE, Smith JW, Steis RG, Urba WJ, Sharfman W, Fenton RG, Creekmore SP, Holmlund J, Conlon KC, VanderMolen LA, Longo DL. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. J Clin Oncol. 1996 Aug; 14(8):2234-41. PMID: 8708712.
      View in: PubMed
    12. Dillman RO, Vandermolen LA, Barth NM, Bransford KJ. Malignant melanoma and pregnancy ten questions. West J Med. 1996 Feb; 164(2):156-61. PMID: 8775729.
      View in: PubMed
    13. Dillman RO, Barth NM, Mahdavi K, VanderMolen LA, Nayak SK, O'Connor A. The integration of high-dose chemotherapy and biotherapy: initial 5-year experience with autologous bone marrow transplantation in a comprehensive community cancer center. Cancer Biother. 1995; 10(1):25-36. PMID: 7780484.
      View in: PubMed
    14. Reed E, Janik J, Bookman MA, Rothenberg M, Smith J, Young RC, Ozols RF, VanderMolen L, Kohn E, Jacob JL. High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer. J Clin Oncol. 1993 Nov; 11(11):2118-26. PMID: 8229126.
      View in: PubMed
    15. Vandermolen LA, Dillman RO. Primary lymphoma of the kidney: complete remission after systemic chemotherapy. J Natl Cancer Inst. 1993 Mar 17; 85(6):505-6. PMID: 8445680.
      View in: PubMed
    16. Sznol M, Clark JW, Smith JW, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. J Natl Cancer Inst. 1992 Jun 17; 84(12):929-37. PMID: 1629914.
      View in: PubMed
    17. Steis RG, Urba WJ, VanderMolen LA, Bookman MA, Smith JW, Clark JW, Miller RL, Crum ED, Beckner SK, McKnight JE. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol. 1990 Oct; 8(10):1618-29. PMID: 2213099.
      View in: PubMed
    18. VanderMolen LA, Duffey PL, Cossman J, Jaffe ES, Longo DL. Surface light chain phenotype in indolent lymphomas: lack of prognostic significance. Am J Hematol. 1990 May; 34(1):15-20. PMID: 2109529.
      View in: PubMed
    19. Steis RG, VanderMolen LA, Lawrence J, Sing G, Ruscetti F, Smith JW, Urba WJ, Clark J, Longo DL. Erythrocytosis in hairy cell leukaemia following therapy with interferon alpha. Br J Haematol. 1990 May; 75(1):133-5. PMID: 2375913.
      View in: PubMed
    20. Steis RG, VanderMolen LA, Longo DL, Clark JW, Smith JW, Kopp WC, Ruscetti FW, Creekmore SP, Elwood LJ, Hursey J. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. J Natl Cancer Inst. 1990 Apr 18; 82(8):697-703. PMID: 2138680.
      View in: PubMed
    21. VanderMolen LA, Steis RG, Duffey PL, Foon KA, Smith JW, Clark JW, Conlon K, Stevenson HC, Urba WJ, Hartmann LC. Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma. J Natl Cancer Inst. 1990 Feb 07; 82(3):235-8. PMID: 2296053.
      View in: PubMed
    22. VanderMolen LA, Urba WJ, Longo DL, Lawrence J, Gralnick H, Steis RG. Diffuse osteosclerosis in hairy cell leukemia. Blood. 1989 Nov 01; 74(6):2066-9. PMID: 2804348.
      View in: PubMed
    23. VanderMolen LA, Smith JW, Longo DL, Steis RG, Kremers P, Sznol M. Adrenal insufficiency and interleukin-2 therapy. Ann Intern Med. 1989 Jul 15; 111(2):185. PMID: 2787137.
      View in: PubMed
    24. Hartmann LC, Urba WJ, Steis RG, Smith JW, VanderMolen L, Creekmore SP, Longo DL. Hypothyroidism after interleukin-2 therapy. J Clin Oncol. 1989 May; 7(5):686-7. PMID: 2785167.
      View in: PubMed
    25. VanderMolen LA, Swain S, Longo DL. Lactic acidosis in lymphoma: prompt resolution of acidosis with therapy directed at the lymphoma. J Natl Cancer Inst. 1988 Sep 07; 80(13):1077-8. PMID: 3411621.
      View in: PubMed
    26. Vandermolen L, Rice L, Rose MA, Lynch EC. Ringed sideroblasts in primary myelodysplasia. Leukemic propensity and prognostic factors. Arch Intern Med. 1988 Mar; 148(3):653-6. PMID: 3341866.
      View in: PubMed
    27. Young JB, Vandermolen LA, Pratt CM. Torsade de pointes: an unusual manifestation of chloral hydrate poisoning. Am Heart J. 1986 Jul; 112(1):181-4. PMID: 3728278.
      View in: PubMed
    28. Vandermolen L, Rice L, Lynch EC. Plasma cell dyscrasia with marrow fibrosis. Clinicopathologic syndrome. Am J Med. 1985 Sep; 79(3):297-302. PMID: 4036981.
      View in: PubMed
    29. Vandermolen LA, Fehir KM, Rice L. Multiple myeloma in a homosexual man with chronic lymphadenopathy. Arch Intern Med. 1985 Apr; 145(4):745-6. PMID: 3920986.
      View in: PubMed